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ABSTRACT Staphylococcus aureus is a clinically signiﬁcant human pathogen that
causes infectious diseases ranging from skin and soft tissue infections (SSTI) and
health care-associated infections (HAI) to potentially fatal bacteremia and endocardi-
tis. Nasal carriage of S. aureus, especially for persistent carriage, is associated with an
increased risk of subsequent infection, particularly nosocomial and surgical site in-
fections (SSI), usually via autoinfection. NP108 is a cationic antimicrobial polymer
composed of generally recognized as safe (GRAS) amino acid building blocks. NP108
is broad spectrum and rapidly bactericidal (3-log kill in 3 h), killing bacteria by
membrane disruption and cell lysis. NP108, contrary to many antibiotics, shows
equally effective antimicrobial activity against a variety of S. aureus (MIC100  8 to
500 mg/liter) and S. epidermidis (MIC100  4 to 8 mg/liter) isolates, whether expo-
nentially growing or in stationary phase. NP108 is antimicrobially active under
nutrient-limiting conditions similar to those found in the anterior nares (MIC100  8
mg/liter) and kills antibiotic-resilient small colony variants (MIC100  32 mg/liter) and
S. aureus bioﬁlms (prevention, MIC100  1 to 4 mg/liter; eradication, MIC100  31.25
mg/liter). NP108 is active against isolates of S. aureus resistant to the current
standard-of-care decolonization agent, mupirocin, with no signiﬁcant increase in the
MIC100. NP108 is water soluble and has been formulated into compatible aqueous
gel vehicles for human use in which antimicrobial efﬁcacy is retained (2.0% [wt/vol]).
NP108 is a potential nonantibiotic antimicrobial alternative to antibiotics for the na-
sal decolonization of S. aureus, with clear advantages in its mechanism of action
over the existing gold standard, mupirocin.
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Staphylococcus aureus is a major human pathogen, despite existing as a commensalcolonizer of the skin in 30% of the global population (1–3). S. aureus is a leading
cause of bacterial health care-associated infections (HAI), including surgical site infec-
tions (SSI), pleuropulmonary infections, skin and soft tissue infections (SSTI), and
osteomyelitis and device-related infections, as well as potentially fatal infections,
including bacteremia, endocarditis, and toxic shock syndrome (1–3). Since the advent
of the antibiotic era, S. aureus has demonstrated a remarkable ability to adapt and
develop resistance to almost all antibiotic classes. Methicillin-resistant Staphylococcus
aureus (MRSA) is resistant to all available penicillins and other -lactams (4) and, in
some cases, other antibiotic classes, including macrolides and tetracyclines (5). Data for
2015 indicate that 10 to 12% of invasive S. aureus isolates in the United Kingdom were
MRSA (6), and there were an estimated 59,000 cases of MRSA infection and 9,670
attributable deaths in the United States in 2012 (7).
Approximately one-quarter to one-third of humans are asymptomatic persistent
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nasal carriers of S. aureus, whereas a further 30% are intermittent carriers (8, 9). Nasal
carriage of S. aureus, especially for persistent carriage, has been positively correlated to
an increased risk of subsequent infection, usually via autoinfection (10–12). The World
Health Organization recently published 29 (13 preoperative and 16 intra- and postop-
erative) global recommendations for the prevention of SSI, including nasal decoloni-
zation with mupirocin ointment in patients with known nasal carriage of S. aureus (13,
14). The frequent overuse of mupirocin has quickly been followed by mupirocin
resistance (low and high level) with some outbreaks of mupirocin-resistant MRSA
reported (15, 16). Mupirocin resistance rates as high as 81% have been reported and are
signiﬁcantly associated with persistent MRSA carriage, decolonization failure, and early
recolonization (17–21).
The emergence of mupirocin resistance and examples of decolonization failure
means that alternative S. aureus decolonization strategies are actively being sought for
both mupirocin nasal decolonization and chlorhexidine gluconate washing (16, 22). The
use of the lysine polymer, NP108, represents one such alternative.
Antimicrobial peptides (AMPs) are key components of the innate immune system,
with examples of AMPs found in all taxonomic kingdoms (23–26). Most endogenous
AMPs are cationic (due to the net charge effect of the arginine and lysine content),
amphipathic, contain 10 to 50 amino acids, and target the anionic microbial cell
membrane, resulting in cell destabilization, membrane lysis, and death (27–30). Poly-
lysines (modiﬁed epsilon forms) have been used as preservatives for a range of dairy
and meat products (31, 32). With this precedent for synthetic/modiﬁed polylysines and
natural, lysine-rich AMPs, we therefore investigated whether simple polymers of natural
lysines were active against antibiotic-sensitive and antibiotic-resistant S. aureus, includ-
ing methicillin-susceptible Staphylococcus aureus (MSSA), MRSA, and mupirocin-sensitive
and -resistant isolates. In this manuscript, we describe the in vitro activity of NP108, a
lysine polymer selected for development for the nasal decolonization of S. aureus
(MSSA and MRSA) and the prevention of HAI. NP108 is a broad-spectrum rapidly acting
bactericidal compound that kills bacterial cells by membrane disruption and cell lysis
through mechanisms aligned with those described for endogenous lysine-rich AMPs
(31). Our data also demonstrate that NP108, as a highly water-soluble polymer, can be
formulated into compatible delivery vehicles for use in humans (application to the
anterior nares) without a loss of antimicrobial efﬁcacy.
RESULTS AND DISCUSSION
Antimicrobial activity of NP108 versus S. aureus and S. epidermidis. The anti-
microbial efﬁcacy of NP108 against a panel of 28 S. aureus (8 MRSA and 20 MSSA)
isolates and 3 S. epidermidis isolates was determined by the broth microdilution
procedure (see Table S1 in the supplemental material) (33). NP108 MIC100 values for all
but two of the isolates tested were in the low milligram per liter range (4 to 64 mg/liter),
and for the two less-NP108-sensitive isolates, higher MICs (500 mg/liter for S. aureus
CB005 and 250 mg/liter for S. aureus CB007) were recorded and compared favor-
ably with those of epsilon-polylysine and other AMPs (31). The minimum bactericidal
concentrations (MBCs) of NP108 against these Staphylococcus species isolates were
determined and all were identical to the MIC100 or within one dilution of the MIC100,
indicating that NP108 is bactericidal after 20 h, unlike mupirocin, which is bacteriostatic
as MBC values (mg/liter) are signiﬁcantly higher than MIC values (Table 1) (34).
In vitro antimicrobial activity of NP108 against low-level mupirocin-resistant
mutants of S. aureus. Mupirocin is a competitive inhibitor of bacterial isoleucyl-tRNA
synthetase, thereby blocking bacterial protein and RNA synthesis (16, 35). Mupirocin
resistance can be categorized as low level (8 to 256 mg/liter) or high level (512
mg/liter), and isolates of MSSA and MRSA with both resistance types have been
described (36–39). Low-level mupirocin-resistant mutants were generated from two
strains of MSSA (S. aureus NCTC10788 and S. aureus NS05R1) and two strains of MRSA
(S. aureus DSMZ11729 and S. aureus NCTC10442). Antibiotic susceptibility testing (Table
2) demonstrated that the mutants were resistant to mupirocin (MIC100  8 to 16
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mg/liter), unlike the isogenic mupirocin-sensitive isolates (MIC100  1 mg/liter). In all
cases, the mupirocin-resistant mutants remained equally sensitive to NP108, and in two
cases (S. aureus DSMZ11729 and S. aureus NS05R1), the NP108 MIC was halved. The
NP108 MIC values between isogenic mupirocin-resistant and mupirocin-sensitive
strains were not statistically signiﬁcant (unpaired t test [GraphPad Prism 4 for Win-
dows]). This demonstrates that there is no evidence of cross-resistance between
low-level mupirocin resistance and NP108 efﬁcacy.
Antimicrobial activity of NP108 against small-colony variants of S. aureus.
Small-colony variants (SCV) of S. aureus are known to have reduced membrane poten-
tial (Δ) compared with that the wild-type (WT) parental strain (40), and this has been
shown to adversely affect aminoglycoside (e.g., gentamicin and tobramycin) antibac-
terial efﬁcacy, as Δ facilitates the uptake of aminoglycoside into bacterial cells (41). A
reduced Δ is also known to adversely affect the efﬁcacy of selected cationic antimi-
crobial peptides (42–44), and as NP108 is cationic, it was deemed relevant to determine
whether the susceptibility of S. aureus SCV to NP108 was affected. In a previous study
that examined the susceptibility of S. aureusWT and SCV to cationic peptides, SCV were
less susceptible to protamine and equally susceptible to magainin and human neutro-
phil peptide-1, but were more susceptible to dermaseptin (45). S. aureus SCV have been
isolated from sinonasal biopsy specimens of chronic rhinosinusitis patients (46) and can
be internalized by and maintained in a human keratinocyte (HaCaT) cell line in vitro (47).
Therefore, SCV may be associated with S. aureus carriage in the anterior nares. SCV of
one strain of MRSA (S. aureus DSMZ11729) and one of MSSA (S. aureus ATCC 25923)
were generated, and their susceptibilities to NP108, mupirocin, and tobramycin were
TABLE 1 Antimicrobial activity of mupirocin against Staphylococcus sppa
Isolate Features
Mean MIC100
(mg/liter)
MBC
(mg/liter)
S. aureus DSMZ11729 MRSA 0.25 4.0
S. aureus NCTC10442 MRSA 0.50 8.0
S. aureus BAA-1717 MRSA 0.50 8.0
S. aureus ATCC 25923 MSSA 0.25 8.0
S. aureus NS05R1 MSSA, nasal isolate 1.00 8.0
S. aureus NCTC10788 MSSA 0.25 4.0
S. aureus NCTC6571 MSSA 0.25 4.0
S. epidermidis ATCC 12228 MSSE 0.25 8.0
S. epidermidis V1A MSSE, nasal isolate 0.50 8.0
aThe MIC at which 100% growth was inhibited (MIC100) and the minimum bactericidal concentration (MBC)
at which all cells were killed by mupirocin were determined by the broth microdilution procedure (55) and
as described in reference 33, respectively. Results represent the means from 3 experiments which each
contained three technical replicates. MSSA, methicillin-sensitive S. aureus; MRSA, methicillin-resistant S.
aureus; MSSE, methicillin-sensitive S. epidermidis.
TABLE 2 Antimicrobial activity of NP108 and mupirocin against S. aureus and isogenic
low-level mupirocin-resistant mutantsa
Isolate
Mean MIC100 (mg/liter)
NP108 Mupirocinb
S. aureus DSMZ11729 (MRSA) 32 0.5 (S)
S. aureus DSMZ11729 (MRSA) Mupr 16 8 (R)
S. aureus NCTC10442 (MRSA) 32 1 (S)
S. aureus NCTC10442 (MRSA) Mupr 32 16 (R)
S. aureus NCTC10788 (MSSA) 8 0.25 (S)
S. aureus NCTC10788 (MSSA) Mupr 8 8 (R)
S. aureus NS05R1 (MSSA) 16 1 (S)
S. aureus NS05R1 (MSSA) Mupr 8 16 (R)
aThe MIC at which 100% growth was inhibited (MIC100) was determined by the broth microdilution
procedure (33). Results represent the means from 3 experiments which each contained three technical
replicates. Mupirocin susceptibility, MIC  4 mg/liter; low-level mupirocin resistance, MIC  8 to 64 mg/
liter; high-level mupirocin resistance, MIC  512 mg/liter (35); MSSA, methicillin-sensitive S. aureus; MRSA,
methicillin-resistant S. aureus; Mupr, mupirocin resistant.
bR, resistant; S, sensitive.
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determined (Table 3). The MIC100 values of NP108 against S. aureus ATCC 25923 WT and
SCV were identical (32 mg/liter), whereas the MIC100 of S. aureus DSMZ11729 SCV was
one dilution higher than the MIC100 of the WT (64 and 32 mg/liter, respectively) (Table
2), indicating that SCV status has little or no effect on NP108 antibacterial efﬁcacy
against these isolates. The MICs of mupirocin were identical for both strains of S. aureus,
whether WT or SCV (0.5 mg/liter). As expected, the susceptibilities of the SCV to the
aminoglycoside antibiotic tobramycin were reduced, with 16-fold increases in MICs
for S. aureus DSMZ11729 (tobramycin resistant and known to be gentamicin resistant
[50 mg/liter]) (48) and S. aureus ATCC 25923 SCV (Table 3). The data were analyzed by
one-way analysis of variance (ANOVA), and the differences in antimicrobial suscepti-
bility between the WT and SCV were not statistically signiﬁcant (P 0.05). Interestingly,
S. aureus ATCC 25923 WT was tobramycin sensitive (MIC100  0.5 mg/liter), whereas S.
aureus ATCC 25923 SCV was of intermediate sensitivity to tobramycin and potentially
resistant (MIC100  8 mg/liter). Despite the fact that S. aureus DSMZ11729 was tobra-
mycin resistant (MIC100  16 mg/liter), there was still an increase in tobramycin MIC
(16-fold) in the SCV isolate (MIC100  256 mg/liter).
Antimicrobial activity of NP108 versus S. aureus under low-nutrient conditions.
The anterior nares are a relatively nutrient-poor environment (49); therefore, for any
antimicrobial intended for application for nasal decolonization, it is essential that
antimicrobial activity is not compromised under nutrient-limiting conditions in which
bacteria are not multiplying or are multiplying slowly. Many antibiotics are not as
efﬁcacious under these conditions (50) and therefore may not be suitable for nasal
decolonization; but, membrane-active compounds may not be subject to such limita-
tions (51). NP108 was more effective under low-nutrient conditions than under high-
nutrient conditions, with the MIC100 reduced by 3-fold under low-nutrient conditions
for both strains of S. aureus (Table 4). Antimicrobial susceptibility differences under low-
and high-nutrient conditions were analyzed by one-way ANOVA. The differences
between NP108 MICs under low- and high-nutrient conditions were statistically signif-
icant (P  0.001), whereas they were not statistically signiﬁcant for mupirocin (P 
0.05). Mupirocin was not adversely affected by low-nutrient conditions, with the MIC100
TABLE 3 Antimicrobial activity of NP108, mupirocin, and tobramycin against wild-type
and SCV of S. aureusa
Isolate
Mean MIC100 (mg/liter)
NP108 Tobramycin Mupirocin
S. aureus DSMZ11729 (MRSA) WT 32 16 0.5
S. aureus DSMZ11729 (MRSA) SCV 64 256 0.5
S. aureus ATCC25923 (MSSA) WT 32 0.5 0.5
S. aureus ATCC25923 (MSSA) SCV 32 8 0.5
aThe MIC at which 100% growth was inhibited (MIC100) was determined by the broth microdilution
procedure (33). Results represent the means from 3 experiments which each contained three technical
replicates. SCV, small-colony variant; WT, wild type. One-way ANOVA was conducted using GraphPad Prism
4 for Windows.
TABLE 4 Antimicrobial activity of NP108 and mupirocin against S. aureus DSMZ11729 and
S. aureus ATCC 25923 under high- and low-nutrient conditionsa
Isolate
Mean MIC100 (mg/liter)
NP108 Mupirocin
High
nutrient
Low
nutrient
High
nutrient
Low
nutrient
S. aureus DSMZ11729 32 8 0.5 0.125
S. aureus ATCC 25923 32 8 0.5 0.5
aAntimicrobial susceptibility testing was conducted by the broth microdilution procedure (33). High-nutrient
condition testing was carried out in 1 CA-MH broth and low-nutrient condition testing was carried out in
0.1 CA-MH broth. Results represent the means from 3 experiments which each contained three technical
replicates. One-way ANOVA was conducted using GraphPad Prism 4 for Windows.
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reduced by 4-fold in the case of S. aureus DSMZ11729 and being unaffected in the case
of S. aureus ATCC 25923.
Kinetics of NP108 killing of exponential- and stationary-phase S. aureus. Most
bactericidal antimicrobials require bacteria that are actively growing/metabolizing to
produce killing, whereas stationary-phase cultures of S. aureus demonstrate signiﬁcant
tolerance to many antibiotics (52, 53). Therefore, the antimicrobial activity of NP108
against exponential-phase and stationary-phase S. aureus DSMZ11729, S. aureus ATCC
25923, S. aureus NCTC10442 mupirocin-sensitive (Mups), and S. aureus NCTC10442
mupirocin-resistant (Mupr) isolates was determined. The kinetics of NP108 (4 MIC) for
killing 4 isolates of S. aureus were such that a 3-log kill was achieved within 3 h of
incubation with an inoculum of 108 CFU/ml of cells (Fig. 1). Stationary-phase cultures
were killed as quickly as exponential-phase cultures. When the isogenic mupirocin-
resistant isolate of S. aureus NCTC10442 was tested, it was killed more rapidly than the
mupirocin-sensitive isolate, demonstrating that there was no evidence of cross-
resistance with mupirocin and NP108. The 108 CFU/ml represents 150-fold more cells
than are used in broth microdilution antimicrobial susceptibility testing (33) but with
only 4-fold more NP108 used. When 4 MBC mupirocin was used against 3 of the
isolates (S. aureus DSMZ11729, S. aureus ATCC 25923, and S. aureus NCTC10442), no
killing was achieved even after 24 h of incubation (data not shown), which correlates
with the slow killing time of mupirocin even at high concentrations (34). It was not
possible to test S. aureus NCTC10442 Mupr with 4MBC of mupirocin, as the mupirocin
MBC (1,024 mg/liter) of this isolate could not be determined due to limits of the
aqueous solubility of mupirocin.
Importance of cationicity for the bactericidal mechanism of action of NP108.
NP108 is a cationic polylysine polymer (molecular weight [MW], 22), and the net
positive charge is thought to be essential for the membrane-acting bactericidal activity
of the compound. To test this hypothesis, the polyanionic compound polyanethole-
sulfonic acid (PASA) was included in the MIC assays along with NP108 and the
antimicrobial efﬁcacy was determined against S. aureus SMRSA105 and S. aureus
EMRSA16 (Fig. 2). The addition of PASA to NP108 eliminated the antibacterial activity
of NP108, while PASA had no effect on S. aureus survival alone. In the absence of PASA,
NP108 rapidly killed both strains of S. aureus, indicating that the cationic properties of
NP108 are essential for antimicrobial activity.
Electron microscopy to determine the effect of NP108 on the cellular morphol-
ogy of S. aureus. NP108 has charge-dependent potent bactericidal effects within 1 h,
as demonstrated in Fig. 2. Scanning and transmission electron microscopy (SEM and
TEM, respectively) were used to investigate the effect of NP108 on the morphology of
S. aureus SMRSA105. SEM analysis of a 60-min treatment with 60 mg/liter NP108
revealed extensive cellular debris with few intact cells (Fig. 3C). The TEM micrographs
(Fig. 3D) revealed that, despite appearing intact, the remaining cells following incuba-
tion with 62.5 mg/liter NP108 no longer contained any internal architecture, unlike in
the untreated control (Fig. 3B). There is also evidence of buckling and bulging of the cell
walls in the treated samples, indicative of a loss of cell integrity and lysis, conﬁrming the
rapid bactericidal action of NP108 targeting the cell surface.
Activity of NP108 against S. aureus bioﬁlms. The antibioﬁlm activity of NP108
against established bioﬁlms of S. aureus ATCC 25923 (MSSA) and S. aureus DSMZ11729
(MRSA) and whether NP108 could prevent bioﬁlm formation by either strain were
assessed (Fig. 4). NP108 disrupted S. aureus bioﬁlms in a concentration-dependent
manner from 31.25 to 500 mg/liter. Interestingly, bioﬁlm prevention was achieved
at lower concentrations (4 to 8 mg/liter) for both strains, which are concentrations
lower than the MIC100 of NP108 against planktonic cells of either strain (32 mg/liter)
(Table S1).
Antimicrobial activity of NP108 prepared as water-soluble formulations. NP108
has a high aqueous solubility (400 g/liter), and so to generate a pharmaceutical
formulation suitable for the application of NP108 to the anterior nares, the develop-
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ment of an aqueous formulation containing NP108 was a logical choice. This choice of
formulation was based on the characteristics required for nasal application, including
the retention of antimicrobial activity, the release of the antimicrobial from the formu-
lation, the ease of application, appropriate hydrophilicity, a lack of irritation, and
appropriate viscosity/rheological properties. NP108 retained antimicrobial activity
against S. aureus ATCC 25923 (see Fig. S1B, D, F, H, and J) and other S. aureus isolates
FIG 1 Effect of NP108 on the survival of S. aureus DSMZ11729 (MRSA), S. aureus ATCC 25923 (MSSA), S. aureus NCTC10442 (MRSA), and S. aureus NCTC10442
Mupr (low-level mupirocin-resistant MRSA) over 6 h of incubation. NP108 was added at 4 MIC to exponential-phase or stationary-phase cultures of the S.
aureus isolates diluted to the 0.5 McFarland standard (108 CFU/ml) at 37°C in CA-MH broth (exponential phase) or conditioned CA-MH broth (stationary phase).
Samples were taken every 60 min and viable counts established by plating on CA-MH agar and incubating for 24 h at 37°C. Untreated cultures were used as
growth controls. Values in the table represent the time taken to kill the isolates of three replicates from 3 independent experiments. The graphs show
representative data from a single experiment with each isolate. Data points represent the mean numbers of CFU/ml within the experiment. Horizontal dotted
lines represent 3-log reduction in CFU/ml (complete kill). Conditioned CA-MH broth was medium derived from cultures of the relevant S. aureus isolate grown
to stationary phase (48 to 54 h), and cells were removed by centrifugation (5 min at 17,000  g) and ﬁlter sterilized (0.22-m PES ﬁlter).
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(data not shown), whereas none of the base formulations not containing NP108
demonstrated any antimicrobial activity (Fig. S1A, C, E, G, and I). Mupirocin (Bactroban
nasal ointment) was also active under the same experimental conditions (Fig. S1K).
Thus, NP108 can be included in suitable pharmaceutical formulations for use in
subsequent human studies.
Our results from these studies describe the in vitro activity and development thus far
of NP108, a novel antimicrobial lysine polymer composed of generally recognized as
FIG 2 The effect of PASA on the antibacterial activity of NP108 against S. aureus MRSA. The inﬂuence of 2% (wt/vol) PASA in
MH broth on the antibacterial efﬁcacy of 62.5 mg/liter NP108 when incubated with S. aureus SMRSA105 (A) or S. aureus
EMRSA16 (B) for 60 min at 37°C (n  9). Data depict the mean numbers of CFU/ml.
FIG 3 Electron micrographs demonstrating the effect of NP108 on S. aureus SMRSA105. (A) SEM,
untreated; (B) TEM, untreated; (C) SEM, 62.5 mg/liter NP108 for 60 min; (D) TEM, 62.5 mg/liter NP108
for 60 min. Bars  200 nm (A and C) and 100 nm (B and D).
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safe (GRAS) amino acid building blocks, for the nasal decolonization of S. aureus (MSSA
and MRSA) and prevention of HAI. NP108 is rapidly bactericidal (99.9% kill within 3 h of
exposure at 4MIC against108 CFU/ml S. aureus) in the mg/liter concentration range
against S. aureus and S. epidermidis and acts via charge-dependent membrane disrup-
tion, resulting in rapid cell lysis. NP108 shows in vitro activity against a variety of S.
aureus and S. epidermidis strains, including nasal isolates, and is equally effective against
exponentially growing or stationary-phase S. aureus and under nutrient-poor condi-
tions similar to those found in the anterior nares (49). NP108 is effective against
antibiotic-resilient small colony variants (SCV) and S. aureus bioﬁlms. NP108 is also
effective against mupirocin-resistant isolates of S. aureus. NP108 is water soluble and
has been formulated into compatible vehicles for use in humans without a loss of
antimicrobial efﬁcacy. Subsequent studies will evaluate the in vivo efﬁcacy of NP108 for
S. aureus nasal decolonization. There is a clear need for a viable and superior alternative
to mupirocin due to the increasing incidence of resistance to/treatment failure by this
antibiotic. For example, NP108 has the potential to be superior due to its rapid
bactericidal activity, which should signiﬁcantly reduce the potential for resistance
development compared with that of the existing relatively slow-acting bacteriostatic
agent mupirocin, the current “gold standard” therapy. In addition, the data presented
FIG 4 Effect of NP108 on prevention of bioﬁlm formation by S. aureus DSMZ11729 (A) and S. aureus ATCC
25923 (B) under low-nutrient conditions simulating the anterior nares. Exponentially growing S. aureus
isolates were diluted to the 0.5 McFarland standard in 0.1 TSB supplemented with 0.05% (wt/vol) glucose,
0.3% (wt/vol) NaCl, and 0 to 16 mg/liter NP108. Bioﬁlms were allowed to establish statically for 96 h at 37°C
before biomass formation was assessed by the crystal violet method. Data sets represent the means from
triplicate experiments and error bars represent the standard errors of the means. Dotted lines represent the
limit of detection. Effect of NP108 on established bioﬁlms of S. aureus DSMZ11729 (C) and S. aureus ATCC
25923 (D) under low-nutrient conditions simulating the anterior nares. S. aureus bioﬁlms were prepared in
0.1 TSB supplemented with 0.05% (wt/vol) glucose and 0.3% (wt/vol) NaCl and allowed to establish
statically for 96 h at 37°C. Subsequently, bioﬁlms were treated with different concentrations of NP108 in
0.1 TSB supplemented with 0.05% (wt/vol) glucose and 0.3% (wt/vol) NaCl for a further 24 h at 37°C
before bioﬁlm biomass eradication was assessed by the crystal violet method. Data points represent the
mean optical densities (at 595 nm) from single experiments and error bars represent the standard errors of
the means.
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here show additional advantages for the use of a lysine polymer as a topical antimi-
crobial on the basis of the similarities of features to endogenous AMP and on the facts
that NP108 is based on GRAS building blocks (GRAS notice 414) and is biodegradable
without cytotoxicity and that -poly–L-lysines have a long history of safe and effective
use as antimicrobials in the food industry (GRAS notices 135 and 336) (54). On the basis
of the in vitro activity data and the potential ease of formulation determined in this
study, NP108 will be taken further into preclinical/clinical development for the nasal
decolonization of S. aureus and the prevention of SSI.
MATERIALS AND METHODS
Growth conditions and reagents. All growth media and chemicals were purchased from Sigma-
Aldrich (UK) unless otherwise stated. S. aureus DSMZ11729 (ATCC 33592) was obtained from the
Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (Germany). S. aureus ATCC 25923, S.
aureus BAA-1717, S. epidermidis ATCC 35984, and S. epidermidis ATCC 12228 were obtained from the
American Type Culture Collection (LGC Standards, UK). S. aureus NCTC10442, S. aureus NCTC10788 (ATCC
6538), and S. aureus NCTC6571 (ATCC 9144) were obtained from the National Collection of Type Cultures
(Public Health England, UK). S. aureus SMRSA105, S. aureus SMRSA124, S. aureus SMRSA161, S. aureus
EMRSA16, S. aureus MRSA8, S. aureus MRSA10, S. aureus MSSA1, S. aureus MSSA2, S. aureus MSSA6, and
S. aureus MSSA8 were all isolated from dermal wounds and were generous gifts from Gail Ferguson and
Isabel Cook of the Medical Microbiology Department, Aberdeen Royal Inﬁrmary (UK). All other isolates
were from the anterior nares of healthy volunteers.
Isolation and characterization of nasal S. aureus. Staphylococcus aureus was isolated from the
noses of healthy volunteers using the protocol described in Investigation of nasal samples, a standard for
microbiology investigations by the Public Health England, UK (55) after obtaining written informed
consent. After their growth, colonies were assessed macroscopically on mannitol salt phenol red (MSPR)
agar for growth and mannitol fermentation, and colonies were examined microscopically following Gram
staining. Samples were further conﬁrmed as S. aureus by the detection of coagulase activity and the
presence of protein A in the cell wall (Staphylo Monotec test kit Plus; Sigma-Aldrich, UK). Samples were
stored at 85°C in cation-adjusted Mueller-Hinton ([CA-MH] Mueller-Hinton broth 2; Sigma-Aldrich, UK)
broth containing 30% (vol/vol) glycerol until required.
Antimicrobial susceptibility testing. The MICs of NP108 and antibiotics (vancomycin, fusidic acid
[Discovery Fine Chemicals Ltd., UK], mupirocin [VWR, UK], and tobramycin [Discovery Fine Chemicals Ltd.,
UK]) were determined by the broth microdilution procedure (33). The MBCs of NP108 and antibiotics
were measured following MIC determination using a 96-well replicator (Thermo Fisher Scientiﬁc). Brieﬂy,
after 20 h of incubation to determine the MICs, a 96-well replicator was used to transfer samples in
triplicates from each well to 140-mm petri dishes containing CA-MH agar (no antimicrobials), which were
incubated at 37°C until good growth was observed for positive (growth) control colonies (56). The MBC
was determined as the lowest concentration of antimicrobial at which no growth was observed.
Antimicrobial susceptibility testing was also carried out on S. aureus growing under low-nutrient
conditions by the broth microdilution procedure (33), except that bacteria were grown in 0.1 CA-MH
broth (one-tenth concentration) rather than normal concentration CA-MH broth.
Generation of low-level mupirocin-resistant isolates. Low-level mupirocin-resistant mutants
(MIC100  8 to 64 mg/liter) were generated by exposing a 0.5 McFarland standard inoculum of
mupirocin-sensitive isolates of S. aureus to doubling concentrations of mupirocin in CA-MH broth every
48 h for up to 16 d with incubation at 37°C, starting at a mupirocin concentration of 0.125 mg/liter on
which all strains were able to grow. Mupirocin-resistant isolates were conﬁrmed as S. aureus by growth
on MSPR agar, macroscopic and microscopic appearance, the detection of coagulase activity, and the
presence of protein A in the cell wall. Mupirocin MICs were determined by the broth microdilution
procedure (33).
Generation of small-colony variants. Small-colony variants (SCV) of S. aureus ATCC 25923 (MSSA)
and S. aureus DSMZ11279 (MRSA) were generated using the method described by Hoffman and
coworkers (57) and characterized as described by Proctor and coworkers (40). SCV and controls were
conﬁrmed as S. aureus by growth on MSPR agar and their macroscopic and microscopic appearance.
Antimicrobial susceptibility testing of SCV for NP018, mupirocin, and tobramycin was performed using
the broth microdilution procedure (33). To maintain the SCV phenotype, 10 mg/liter 2-heptyl-4-
hydroxyquinoline N-oxide (HQNO) was added to SCV cultures to prevent reversion to the wild-type
phenotype, and SCV cultures were incubated until good growth was obtained in the untreated SCV
controls (48 to 72 h) to compensate for the low growth rate of SCV.
Generation of S. aureus bioﬁlms and bioﬁlm eradication. Bioﬁlms of S. aureus ATCC 25923 (MSSA)
and S. aureus DSMZ11729 (MRSA) were generated using the microtiter plate bioﬁlm assay procedure
described by Cassat and coworkers (58) with the following modiﬁcations. The S. aureus culture was
resuspended to the 0.5 McFarland standard in 0.1 tryptic soy broth ([TSB] 1:10 dilution of normal
concentration TSB) supplemented with 0.05% (wt/vol) glucose and 0.3% (wt/vol) NaCl, and 200 l was
added to each well following the aspiration of plasma. Bioﬁlms were established and treated in lower
concentrations of growth medium to simulate the nutrient-poor conditions of the anterior nares (49).
Plates were incubated statically at 37°C for 96 h to allow the bioﬁlms to establish. For bioﬁlm eradication
studies, planktonic bacteria were removed from the wells after 96 h by gentle aspiration, and all wells
were washed 3 times with sterile phosphate-buffered saline ([PBS] Thermo Fisher Scientiﬁc Ltd., UK).
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Antimicrobials (NP108 or mupirocin) dissolved in 0.1 TSB supplemented with 0.05% (wt/vol) glucose
and 0.3% (wt/vol) NaCl were added to the relevant wells and incubated at 37°C for 24 h. Following
treatment, bioﬁlms were visualized by staining with crystal violet (59) to determine the amount of bioﬁlm
that had been eradicated relative to untreated control wells.
Kinetics of NP108 bactericidal activity. To determine the time that NP108 took to kill S. aureus, four
isolates were assessed: S. aureus DSMZ11729 (MRSA), S. aureus ATCC 25923 (MSSA), S. aureus NCTC10442
(MRSA), and S. aureus NCTC10442 Mupr (low-level mupirocin-resistant MRSA). S. aureus NCTC10442 Mupr
was generated at an earlier stage in this study (see above). For determination of the killing kinetics of
exponentially growing S. aureus, cultures were diluted to the 0.5 McFarland standard, and 100 l was
inoculated into 10 ml CA-MH broth and grown overnight (16 to 18 h) at 37°C without shaking. For
determination of the killing kinetics of stationary-phase S. aureus cultures, isolates were grown as
described above but for 48 h. These time points had been previously determined to represent cultures
in the exponential or stationary phase in preliminary experiments (data not shown). For exponentially
growing cultures, samples of S. aureus were diluted to the 0.5 McFarland standard in CA-MH broth
(prewarmed to 37°C) before exposure to NP108. For stationary-phase cultures, samples of S. aureus were
diluted to the 0.5 McFarland standard in conditioned CA-MH broth (prewarmed to 37°C) before exposure
to NP108. Conditioned CA-MH broth was prepared by growing the relevant isolate in CA-MH broth for
48 to 54 h, followed by the removal of cells by centrifugation (17,000  g for 5 min), ﬁlter sterilization
(0.22-m polyethersulfone [PES] syringe ﬁlter; Jet Bioﬁl), and storage at 20°C until required. Cultures of
S. aureus were exposed to 4 MICs of NP108, and samples were removed hourly for 24 h. Samples were
serially diluted in sterile PBS and plated on CA-MH agar plates and incubated for at least 24 h before
colonies were enumerated.
Determination of the effect of cationicity on antibacterial activity of NP108. 250 ml ﬂasks of
sterile 20 ml CA-MH broth were inoculated with an overnight culture of S. aureus SMRSA105 or S. aureus
EMRSA16 (OD625  0.005) and incubated at 37°C with shaking (200 rpm) until OD625  0.1 to 0.3
(logarithmic growth). One half of the ﬂasks were supplemented with PASA, a polyanionic compound
used to neutralize the antimicrobial activity of cationic antimicrobial peptides (60), to a ﬁnal concentra-
tion of 2.0% (wt/vol), immediately followed by the addition of 125 mg/liter NP108 (2 MIC100), 16
mg/liter vancomycin hydrochloride (2 MIC100), or 4 mg/liter fusidic acid, sodium salt (2 MIC100)
(Discovery Fine Chemicals Ltd., UK) prepared in sterile CA-MH broth to the ﬂasks with and without PASA.
The cultures were incubated statically at 37°C, and at each speciﬁc time point (15, 30, and 60 min), a
0.02-ml aliquot was removed. Ten-fold serial dilutions to 107 were prepared in CA-MH broth, and each
dilution was spread in triplicate onto CA-MH agar and incubated at 37°C until colonies were observable
(24 h) in the untreated inoculated controls. Colonies were counted, and the percentage kill was
determined based on the reduction in CFU (CFU/ml) in the treated samples relative to the untreated
controls.
Electron microscopy to determine the effect of NP108 on the cellular morphology of S. aureus.
Flasks (250 ml) containing 20 ml sterile CA-MH broth were inoculated with an overnight culture of S.
aureus SMRSA105 (optical density at 625 nm [OD625]  0.005) and incubated at 37°C with shaking (200
rpm) until an OD625 of 0.1 to 0.3 was achieved (logarithmic growth). Bacteria (500 l from 10 ml for SEM)
were added to an equal volume of CA-MH broth with 125 mg/liter NP108 (2 MIC100). NP108 and
bacteria were incubated statically at 37°C for 30 min or 60 min followed by the addition of 2% (wt/vol)
PASA and centrifugation (10 min at 13,000  g). The cell pellets were resuspended and ﬁxed in 1 ml 5%
(wt/vol) glutaraldehyde in 0.2 M sodium phosphate buffer (pH 7.2) and were stored at 4°C. For SEM, cells
were processed using a series of ethanol and hexamethyldisilazane dehydration procedures before gold
mounting. For TEM, cells were dehydrated through a series of ethanol and acetone steps before being
embedded in wax resin, stained with uranyl-acetate lead citrate to improve contrast, sectioned at 90 nm,
and mounted onto copper grids. TEM and SEM micrographs were taken on a JEM-1400 Plus JEOL
transmission electron microscope and a Zeiss EVO MA10 scanning electron microscope, respectively.
Formulation of NP108 into aqueous hydrogels and antimicrobial susceptibility testing. Sterile
(autoclaved at 121°C for 20 min) water-soluble formulations containing NP108 were prepared. NP108 was
aseptically added to all formulations at a concentration of 2.0% (wt/vol). Formulations without NP108
served as vehicle controls, and Bactroban nasal ointment (2.0% [wt/wt] mupirocin calcium) was used as
an antibiotic kill control.
Antimicrobial susceptibility testing was carried out using S. aureus ATCC 25923 grown overnight on
CA-MH agar plates at 37°C. The culture was diluted to the 0.5 McFarland standard in sterile PBS (108
CFU/ml), spread plated on the surface of CA-MH plates made with 1.5% (wt/vol) ultra-high-resolution
agarose (Melford Laboratories Ltd., UK) in place of agar to reduce electrostatic interactions that occur
with the negatively charged sulfate and sugar components of the agaropectin in agar (61), and allowed
to dry for 10 min at room temperature. Aliquots (0.2 ml) of formulations containing NP108 and
formulation only controls were placed in the center of the lawn of S. aureus ATCC 25923 and incubated
for 16 to 18 h at 37°C. Antimicrobial efﬁcacy was demonstrated by a zone of no bacterial growth around
the site of application of the formulation or Bactroban nasal ointment.
SUPPLEMENTAL MATERIAL
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